Acadia Will Outperform, Worth $48/Share Says Leerink
Benzinga By Jim Swanson
April 16, 2015 9:39 AM
In a report published Thursday, Leerink analysts initiated coverage of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) with an Outperform rating and a price target of $48. The delay in receiving the pimavanserin NDA and the retirement of CEO Uli Hacksell has provided an attractive entry point for investors, the analysts said.
Acadia's shares are currently trading 19 percent below its previous highs due to the NDA delay and the retirement of its long-standing CEO. The analysts believe that the company's breakthrough drug NUPLAZID (pimavanserin) is likely to receive approval for the treatment of Parkinson's Disease Psychosis by mid-2016.
"Pimavanserin is a 5HT2a receptor inverse agonist with strong efficacy and an exceptionally clean safety profile, rendering it differentiated from other anti-psychotics which are either modestly effective in PDP, poorly tolerated, and/or increase morbidity/mortality in elderly patients," the analysts explained.
Unlike existing drugs for Parkinson's, pimavanserin does not affect with dopamine receptors, which could interfere with the working of other Parkinson's drugs. "Pimavanserin's efficacy was validated in a pivotal PDP study which met its primary endpoint and also showed statistically significant improvements in clinician and caregiver burden," the analysts added.
The drug could also prove effective in the treatment of Alzheimer's Disease Psychosis, for which the analysts expect the company to release clinical data in 1H16.
- Shares of Irish drug developer Prothena surged Friday after the company reported promising results from an early-stage study of a drug designed to treat Parkinson's disease.
Prothena said the study showed the drug, PRX002, was safe, without serious side effects, and that it reduced levels of a protein that is believed it be associated with the disease. The drug was tested on 40 healthy people, which is common in early clinical trials of experimental drugs. Prothena is conducting studies that will involve more people, including patients who suffer from the disease.
Prothena stock was up $8.26, or 28 percent, to $37.49 in afternoon trading. It hit $45 earlier in the day.
PRX002 is designed to reduce levels of free serum alpha-synuclein. When that protein builds up in the brain, it is associated with Parkinson's disease and related conditions.
Wedbush analyst Heather Behanna said the study is an important first step for Prothena, but it's not clear if the drug will work on humans the same way it has worked in preclinical models. Behanna rates Prothena shares "Outperform" with a price target of $46.
Dublin-based Prothena Corp. announced a development deal with Roche in December 2013. The company says it could get as much as $600 million in milestone payments from Roche, as well as a portion of profits and royalty payments on sales of the drug if it is approved. Prothena has received $45 million so far.
One other Company last week declared and were approved for treating the same medical problems ACAD supposed to have a breakthrough in the same diseases. sorry I cannot remember the name - but the stock soared on the approval news.
momoney163 Saturday, 11/24/12 12:24:38 AM
Post # of 1549
ACAD halted today around 1. Big buyout coming!
See why we cannot count on printed 'NEWS:
They are like leeches - and no wonder people have little or no respect for these greedy grabbers!
Personally I believe they are wasting their time - and ours!